RZLT
Rezolute, Inc.Company Information
- Company Name
- Rezolute, Inc.
- CIK
- CIK0001509261
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- RZLT: Nasdaq
- Fiscal Year End
- June 30
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- RZLT
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-03-30
- Last sale
- —
- Shares purchased (TTM)
- 1,386,402
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 87,101,875
- Shares outstanding
- 104,040,292
- Ownership
- 83.72%
Earnings Market Reaction
- Filing date
- 2026-09-24
- Price on filing date
- —
- 1-month reaction
- Pending
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 11 | 11 | 12 | 9 | 94 | 15 | 9 | 10 | 70 | 6 | 13 | 8 | ||||||
| Marketable Securities Current | 97 | 109 | 121 | 143 | 74 | 72 | 88 | 98 | 56 | 74 | 80 | 91 | ||||||
| Prepaid Expense And Other Assets Current | 3 | 2 | 2 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | ||||||
| Assets Current | 111 | 122 | 135 | 155 | 171 | 89 | 99 | 110 | 129 | 82 | 96 | 103 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Deposits Assets Noncurrent | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 0 | 0 | ||||||
| Marketable Securities Noncurrent | - | - | - | - | - | 2 | 9 | 10 | 0 | 2 | 3 | 8 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 113 | 125 | 139 | 159 | 175 | 95 | 112 | 123 | 133 | 88 | 102 | 113 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 5 | 3 | 4 | 3 | 6 | 7 | 3 | 2 | 5 | 3 | 4 | 2 | ||||||
Accrued Liabilities Current | ||||||||||||||||||
| Employee Related Liabilities Current | 2 | 1 | 2 | 3 | 2 | 1 | 4 | 3 | 2 | 1 | 2 | 2 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 11 | 8 | 10 | 10 | 12 | 11 | 11 | 8 | 10 | 7 | 8 | 7 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | ||||||
| Embedded Derivative Fair Value Of Embedded Derivative Liability | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 12 | 9 | 11 | 11 | 13 | 12 | 12 | 10 | 12 | 17 | 10 | 9 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 582 | 578 | 573 | 569 | 566 | 462 | 460 | 458 | 450 | 377 | 381 | 379 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | -0 | 0 | 0 | 0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -481 | -461 | -445 | -422 | -404 | -379 | -361 | -345 | -329 | -306 | -289 | -276 | ||||||
| Stockholders Equity | 101 | 117 | 128 | 147 | 162 | 83 | 100 | 113 | 121 | 71 | 92 | 104 | ||||||
| Liabilities And Stockholders Equity | 113 | 125 | 139 | 159 | 175 | 95 | 112 | 123 | 133 | 88 | 102 | 113 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 165 | 165 | 165 | 165 | 165 | 165 | 165 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 96 | 96 | 96 | 91 | 87 | 61 | 61 | 55 | 53 | 40 | 40 | 37 | ||||||
| Shares Outstanding | 96 | 96 | 96 | 91 | 87 | 61 | 61 | 55 | 53 | 40 | 40 | 37 | ||||||
Select a line item above to chart it.
Recent filings
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialRezolute, Inc. (RZLT) — SEC Financial Statements & Analysis
Rezolute, Inc. (RZLT) is a pharmaceutical preparations company, incorporated in NV. Rezolute, Inc. trades on Nasdaq as: RZLT. Rezolute, Inc. (RZLT)'s most recent SEC filing is a Form 10-K for the period ended 2026-06-30, filed with the SEC on 2026-09-24. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Rezolute, Inc. carries a market cap of $540.32M, a P/E ratio of -6.96x, a P/B ratio of 5.37x, an enterprise value of $529.70M, and an EV/EBITDA multiple of -6.39x. On profitability, it posts a Return on Equity (ROE) of -59.04%, a Return on Assets (ROA) of -53.82%, and a Return on Invested Capital (ROIC) of -86.38%. Per share, it reports EPS of $-0.75, diluted EPS of $-0.75, free cash flow per share of $-0.62, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 4.27% year-over-year and EPS growth of -23.74% year-over-year. On the balance sheet, it maintains a current ratio of 9.68x, a quick ratio of 9.44x, working capital of $99.09M, a debt-to-equity ratio of 0.12x, a debt ratio of 0.11, free cash flow of $-64.64M (TTM), and net debt of $-10.62M. Figures sourced from SEC EDGAR.
- Market Cap
- $540.32M
- P/E TTM
- -6.96x
- EPS TTM
- $-0.75
- P/B TTM
- 5.37x
- ROE TTM
- -59.04%
- ROA TTM
- -53.82%
- Debt To Equity
- 0.12x
- Free Cash Flow TTM
- $-64.64M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Rezolute, Inc. in?
Rezolute, Inc. (RZLT) operates in the Pharmaceutical Preparations industry.
What exchange does RZLT trade on?
Rezolute, Inc. (RZLT) trades on the Nasdaq.
Where is Rezolute, Inc. incorporated?
Rezolute, Inc. is incorporated in NV.
When was Rezolute, Inc. (RZLT)'s most recent SEC filing?
Rezolute, Inc. (RZLT)'s most recent SEC filing is a Form 10-K for the period ended 2026-06-30, filed with the SEC on 2026-09-24.
What is RZLT's market cap?
Rezolute, Inc. (RZLT) has a market capitalization of $540.32M as of 2026-06-30.
What is RZLT's EPS (earnings per share)?
Rezolute, Inc. (RZLT)'s trailing twelve month EPS is $-0.75 as of 2026-06-30.
What is RZLT's ROE (return on equity)?
Rezolute, Inc. (RZLT)'s trailing twelve month Return on Equity (ROE) is -59.04% as of 2026-06-30.
What is RZLT's ROA (return on assets)?
Rezolute, Inc. (RZLT)'s trailing twelve month Return on Assets (ROA) is -53.82% as of 2026-06-30.
What is RZLT's ROIC (return on invested capital)?
Rezolute, Inc. (RZLT)'s trailing twelve month Return on Invested Capital (ROIC) is -86.38% as of 2026-06-30.
What is RZLT's EV/EBITDA?
Rezolute, Inc. (RZLT)'s trailing twelve month EV/EBITDA is -6.39x as of 2026-06-30.